Shots:

• BioMotiv and BMS launch its first company- Anteros Pharmaceutical under a collaboration signed b/w the companies in Sept’2019
• BMS will provide the IP- data and reagents for a series of small molecules while BioMotiv- working in collaboration with Yale will be solely responsible for research and development. Following the nomination of Anteros’ preclinical candidate- BMS has the option to acquire Anteros under pre-agreed terms
• Anteros will focus on refining a new class of therapies for fibrotic and inflammatory diseases targeting unmet medical needs of millions of patients

Click here ­to­ read full press release/ article 

Ref: BMS | Image: BMS